MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.kint.2026.06.050

Медицинская библиотека · Kidney international · 2026

Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria.

Bhatt Nirmal P, Nguyen Theresa T H, Iacono Giulia, Rodriguez Gabriel R, Anderson Connor R B, Perry Andrew, Barlow Christopher K, Anderson Dovile, Burgio Gaetan, Marsland Benjamin J, Jiang Simon H, Deshpande Aniruddh V, Starkey Malcolm R

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Cystinuria is a rare inherited disease characterized by increased urinary cystine levels resulting in the formation of cystine stones in the urinary tract. Mutations in the genes encoding the cystine transporter complex, SLC3A1 and SLC7A9, are the primary drivers of the disease. Current mouse models used to study cystinuria rely on gene deficiency or spontaneous mutations in mice that do not accurately reflect the pathogenic mutations found in humans.

METHODS

We generated a novel Slc7a9G105R knock-in mouse model in which glycine at position 105 is replaced by arginine, recapitulating the most common pathogenic mutation in human SLC7A9. Disease onset and progression were assessed using micro-CT imaging, fecal metagenomics, and urine and serum metabolomics and proteomics.

RESULTS

Both male and female Slc7a9G105R mice developed a cystinuria phenotype by nine weeks of age, characterized by substantial cystine stone formation and increased urinary cystine, lysine, arginine, and ornithine. Slc7a9G105R mice displayed distinct serum and urinary metabolite profiles, mapped to dibasic amino acid pathways, and serum protein profiles, mapped to disease progression. Fecal metagenomics revealed that Slc7a9G105R mice had a heterogeneous microbiota with altered functional pathways, including increased L-cysteine biosynthesis. Antibiotic-induced depletion of the microbiota did not affect cystine stone burden but reduced urinary tract inflammation. Prophylactic or therapeutic dietary supplementation with alpha-lipoic acid reduced stone burden and inflammation, but it also caused urothelial damage. Untargeted metabolomics analysis following alpha-lipoic acid supplementation identified metabolites that can increase cystine solubility, reduce inflammation, and damage epithelial cells. Correlation analysis revealed novel serum metabolite biomarkers of stone burden, including 2-hydroxybutyric acid and 2-amino-2-thiazoline-4-carboxylic acid, which were also detected in human serum.

CONCLUSIONS

Collectively, the Slc7a9G105R mutant mouse model offers a precise, rapid-onset, and translational platform for investigating cystinuria pathogenesis and evaluating potential therapeutic strategies.

Для цитирования: Bhatt Nirmal P, Nguyen Theresa T H, Iacono Giulia, Rodriguez Gabriel R, Anderson Connor R B, Perry Andrew, Barlow Christopher K, Anderson Dovile, Burgio Gaetan, Marsland Benjamin J, Jiang Simon H, Deshpande Aniruddh V, Starkey Malcolm R. Generation of a novel Slc7a9G105R mutant mouse identifies new biomarkers for cystinuria.. Kidney international. 2026. DOI: 10.1016/j.kint.2026.06.050.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.